TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37328751

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behaviour therapy (CaCBT)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Culturally adapted family intervention (CulFI)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 390
Study: 37328761

Group type: EXPERIMENTAL
Intervention: RTEL1 ultra-rare variants
Number of subjects: 2246
Study: 37328797

Group type: EXPERIMENTAL
Intervention: COMB group (n=64): 16 weeks of exercise training plus the BCE programme
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: EXER group (n=65): exercise training and health talks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (n=55): only health talks
Number of subjects: 184
Study: 37328810

Group type: EXPERIMENTAL
Intervention: Family Navigation (FN) intervention
Number of subjects: 28
Study: 37328813

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle-promoting practice implementation
Number of subjects: 27
Study: 37328817

Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral block
Number of subjects: 82

Group type: COMPARATOR
Intervention: Erector Spinae Plane Block
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 82
Study: 37328835

Group type: COMPARATOR
Intervention: Full dose gemcitabine (Gem)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reduced dose gemcitabine and nab-paclitaxel (GemNab)
Number of subjects: 100
Study: 37328839

Group type: EXPERIMENTAL
Intervention: Numen Coil
Number of subjects: 124

Group type: COMPARATOR
Intervention: Axium Coil
Number of subjects: 124
Study: 37328855

Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) at 220 kHz with systemically administered microbubbles, administered in three successive procedures at 2 week intervals.
Number of subjects: 8
Study: 37328859

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No calcium supplementation (Control)
Number of subjects: 30
Study: 37328890

Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg IV infusion
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotrovimab 2000 mg IV infusion
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotrovimab (dosing intervals to be defined)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 37328931

Group type: EXPERIMENTAL
Intervention: semaglutide 0.1 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: semaglutide 0.2 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: semaglutide 0.4 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: semaglutide (all doses pooled)
Number of subjects: 320

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 320
Study: 37329220

Group type: EXPERIMENTAL
Intervention: 2-year lifestyle intervention
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 421
Study: 37329361

Group type: EXPERIMENTAL
Intervention: Three preoperative intravitreal (IVI) aflibercept injections with a monthly interval; the third injection was given intra-operatively (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single intra-operative injection and two post-operative injections with a monthly interval (Group B)
Number of subjects: 40
Study: 37329412

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization-first (EVR-1st) strategy
Number of subjects: 157
Study: 37329415

Group type: EXPERIMENTAL
Intervention: Bamlanivimab and etesevimab (BAM + ETE) - open-label weight-based dosing (WBD, n=94)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Bamlanivimab and etesevimab (BAM + ETE) - treated adolescent participants (n=20)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Bamlanivimab and etesevimab (BAM + ETE) - overall pediatric population (n=128)
Number of subjects: 128
Study: 37329423

Group type: EXPERIMENTAL
Intervention: RAM+ERL
Number of subjects: 56

Group type: COMPARATOR
Intervention: ERL+PBO
Number of subjects: 56
Study: 37329468

Group type: EXPERIMENTAL
Intervention: Sleep Disturbance Numerical Rating Scale (SD NRS)
Number of subjects: 21
Study: 37329633

Group type: EXPERIMENTAL
Intervention: Chios Mastiha Essential Oil (CMEO) 200 mg daily for 3 months
Number of subjects: 94
Study: 37329655

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation stretching
Number of subjects: 24

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 24
Study: 37329785

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPostC) - four cycles of 5-min inflation to a pressure of 200 mmHg followed by 5 min of deflation on healthy upper limbs once a day for 30 days.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (shame) - patients' diastolic BP followed by 5 min of deflation on healthy upper limbs once a day for 30 days.
Number of subjects: 132
Study: 37329889

Group type: EXPERIMENTAL
Intervention: Group A (FOLFOXIRI-bevacizumab)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Group B (another induction regimen)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Group C (another induction regimen)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Group D (another induction regimen)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Group D
Number of subjects: 530
Study: 37329891

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 6.4 mg/kg intravenously every 3 weeks until disease progression, withdrawal, physician decision, or death
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 79
Study: 37329900

Group type: EXPERIMENTAL
Intervention: KAN-101 (0.15 mg/kg, 0.3 mg/kg, 0.6 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: KAN-101 (all doses)
Number of subjects: 41
Study: 37329951

Group type: EXPERIMENTAL
Intervention: ACTION app
Number of subjects: 81
Study: 37329979

Group type: EXPERIMENTAL
Intervention: 2x taVNS (twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1x taVNS (once daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infants of diabetic mothers
Number of subjects: 21
Study: 37330125

Group type: EXPERIMENTAL
Intervention: Physician awareness of patients' preferred involvement in decision-making before the visit
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (physician unaware of patients' preferences)
Number of subjects: 100
Study: 37330252

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Baseline PA enjoyment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Baseline PA
Number of subjects: 56
Study: 37330256

Group type: EXPERIMENTAL
Intervention: Attributional reframing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpretation bias modification treatment
Number of subjects: 0
Study: 37330257

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Light Therapy
Number of subjects: 177
Study: 37330484

Group type: EXPERIMENTAL
Intervention: Bioclear matrix with injection molding technique
Number of subjects: 26

Group type: COMPARATOR
Intervention: Celluloid conventional matrix method
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 26
Study: 37330500

Group type: EXPERIMENTAL
Intervention: PL EMG biofeedback (BF) neuromuscular training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study: 37330512

Group type: EXPERIMENTAL
Intervention: Awake prone position plus usual care
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 268
Study: 37330602

Group type: EXPERIMENTAL
Intervention: Casirivimab + Imdevimab monoclonal antibody (mAb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 0
Study: 37330704

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT), performed three times per week for 6 weeks.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 40
Study: 37330702

Group type: EXPERIMENTAL
Intervention: Fenestrated and branched endovascular aortic aneurysm repair (F/B-EVAR)
Number of subjects: 2413
Study: 37330928

Group type: EXPERIMENTAL
Intervention: Restrictive IV fluid therapy
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Standard IV fluid therapy
Number of subjects: 1554
Study: 37330974

Group type: EXPERIMENTAL
Intervention: Lumbar drain (5 mL per hour) started within 72 hours after aneurysmal subarachnoid hemorrhage
Number of subjects: 287

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Lumbar drain (5 mL per hour)
Number of subjects: 287
Study: 37331225

Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 3
Study: 37331280

Group type: EXPERIMENTAL
Intervention: PARTNER-MH intervention
Number of subjects: 13
Study: 37331350

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP) followed by Hybrid Snare Polypectomy (HSP)
Number of subjects: 39
Study: 37331369

Group type: EXPERIMENTAL
Intervention: Fruquintinib (5 mg capsule) orally once daily on days 1-21 in 28-day cycles
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 37331368

Group type: EXPERIMENTAL
Intervention: Etripamil 70 mg nasal spray
Number of subjects: 692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study: 37331464

Group type: EXPERIMENTAL
Intervention: 24-hour trough concentration measurements (C)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Single-time trough concentration measurements at steady state
Number of subjects: 19
Study: 37331690

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050

Group type: EXPERIMENTAL
Intervention: Intravenous diuretics (HFH event type)
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Randomized treatment groups
Number of subjects: 5050
Study: 37331928

Group type: EXPERIMENTAL
Intervention: Transpalpebral external microcurrent electrical stimulation with the MacuMira device, 4 treatments in the first 2 weeks, and 2 further treatments at weeks 14 and 26.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham control group (no active treatment).
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transpalpebral external microcurrent electrical stimulation with the MacuMira device.
Number of subjects: 62
Study: 37331992

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pooled tofacitinib
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 37332066

Group type: EXPERIMENTAL
Intervention: Vilobelimab
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 37332136

Group type: EXPERIMENTAL
Intervention: Atacicept (150 mg once weekly)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 503
Study: 37332340

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) followed by chemotherapy and immunotherapy
Number of subjects: 171
Study: 37332355

Group type: EXPERIMENTAL
Intervention: HFB30132A monoclonal antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37332391

Group type: EXPERIMENTAL
Intervention: Educational support for clinicians using electronic patient-reported outcomes (ePROs) and clinician-oriented education via voluntary workshops.
Number of subjects: 543
Study: 37332478

Group type: EXPERIMENTAL
Intervention: Mr. MAPP (mixed reality system) used at home for 1 month
Number of subjects: 0
Study: 37332586

Group type: EXPERIMENTAL
Intervention: Educational intervention (in person, online, application-based)
Number of subjects: 1979

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1979
Study: 37332615

Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) administered at 50 IU/kg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII)
Number of subjects: 4
Study: 37332638

Group type: EXPERIMENTAL
Intervention: Dopamine system-related biomarkers assessed by serial Iodine-123 Ioflupane dopamine transporter (DAT) imaging, genotyping, and levodopa equivalent daily dose (LEDD) recorded at each assessment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment, detailed neuropsychological test battery, Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) cognition score, site investigator diagnosis of CI (mild cognitive impairment or dementia).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate longitudinal analyses with adjustment for multiple comparisons.
Number of subjects: 0
Study: 37332660

Group type: EXPERIMENTAL
Intervention: Low-dose ambrisentan
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-dose ambrisentan
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ambrisentan (both doses)
Number of subjects: 41
Study: 37333093

Group type: EXPERIMENTAL
Intervention: SOMAscan analysis of plasma proteins at baseline (PREOP)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: SOMAscan analysis of plasma proteins on postoperative day 2 (POD2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination of age, sex, and three proteins (ANGPT2, CCL5, TIMP1)
Number of subjects: 57
Study: 37333109

Group type: EXPERIMENTAL
Intervention: SIRI Checklist
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SIRI Checklist + Enhanced Peer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enhanced Peer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 60
Study: 37333146

Group type: EXPERIMENTAL
Intervention: pool-REST
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: pool-REST preferred
Number of subjects: 75

Group type: COMPARATOR
Intervention: chair-REST
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 75
Study: 37333204

Group type: EXPERIMENTAL
Intervention: L-citrulline 60 mg/kg every 6 hours for 72 hours
Number of subjects: 6
Study: 37333263

Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (DDS)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Poor mental health days
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Higher HbA1c
Number of subjects: 415
Study: 37333396

Group type: EXPERIMENTAL
Intervention: QSM (Quantitative Susceptibility Mapping)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DCEQP (Dynamic Contrast Enhanced Quantitative Perfusion)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: QSM
Number of subjects: 143
Study: 37333529

Group type: EXPERIMENTAL
Intervention: Native Opportunities to Stop Hypertension (NOSH) intervention, which includes eight weekly tailored telenutrition counseling sessions with a registered dietitian on DASH eating goals and $30 weekly for purchasing DASH-aligned foods.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving printed educational materials about a low-sodium diet and eight weekly $30 grocery orders.
Number of subjects: 0
Study: 37333547

Group type: EXPERIMENTAL
Intervention: Dietary intake (FFQ), physical activity (PA), sedentary behavior (SB) assessed using Actigraph GT3X accelerometers in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) assessed using Actigraph GT3X accelerometers in men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paternal dietary intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in PA and SB
Number of subjects: 0
Study: 37333664

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 1764

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Propofol (per-protocol analysis)
Number of subjects: 1764

Group type: COMPARATOR
Intervention: Sevoflurane (per-protocol analysis)
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Overall survival (both groups)
Number of subjects: 1764
Study: 37333833

Group type: EXPERIMENTAL
Intervention: High-definition home-based transcranial alternating current stimulation (HB-tACS) at 40 Hz for 20 minutes, targeting the left angular gyrus, administered over 14 weeks with at least five sessions per week.
Number of subjects: 8
Study: 37333911

Group type: EXPERIMENTAL
Intervention: e-predictD intervention + care-as-usual (CAU)
Number of subjects: 720

Group type: COMPARATOR
Intervention: active-control + CAU
Number of subjects: 720
Study: 37333922

Group type: EXPERIMENTAL
Intervention: Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) in neurodegenerative disorders (ND)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) in major depressive disorder (MDD)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Comparison of QIDS-SR between ND and MDD cohorts
Number of subjects: 637
Study: 37333974

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus GEMOX (gemcitabine and oxaliplatin)
Number of subjects: 32
Study: 37334017

Group type: EXPERIMENTAL
Intervention: Uncontrolled severe asthma (ACT score <20)
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Controlled severe asthma (ACT score ≥20)
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: Uncontrolled severe asthma
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Controlled severe asthma
Number of subjects: 1652
Study: 37334213

Group type: EXPERIMENTAL
Intervention: 6-month 45-mg leuprolide acetate (LA) depot, administered intramuscularly at weeks 0 and 24
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6-month 45-mg leuprolide acetate (LA) depot
Number of subjects: 45
Study: 37334295

Group type: EXPERIMENTAL
Intervention: 16 g of carbohydrates (CHO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 32 g of carbohydrates (CHO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Additional 16 g of carbohydrates (CHO) if PG was still <3.0 mmol/L at 15 min and <4.0 mmol/L at 45 min post-initial treatment
Number of subjects: 16
Study: 37334358

Group type: EXPERIMENTAL
Intervention: PMA-stimulated neutrophils
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Indirect ELISA for autoantibodies to Collagen-V, MPO, TREM1, and EPX
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Indirect ELISA for autoantibodies to EPX
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: oxPTM proteins
Number of subjects: 17
Study: 37334496

Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 9
Study: 37334511

Group type: EXPERIMENTAL
Intervention: Rituximab plus multiagent chemotherapy in Ph-negative ALL
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rituximab plus multiagent chemotherapy in Ph-positive ALL
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rituximab after transplantation (≥ 2 cycles)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Higher CD20 positivity in Ph-negative ALL
Number of subjects: 73
Study: 37334546

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRA) treatment for at least 6 months
Number of subjects: 208
Study: 37334655

Group type: EXPERIMENTAL
Intervention: DREAMS 3G magnesium scaffold
Number of subjects: 116
Study: 37334673

Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa plus pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (selected by treating physician)
Number of subjects: 0
Study: 37334784

Group type: EXPERIMENTAL
Intervention: Single sitting scaling and root planing
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Supragingival scaling followed by subgingival instrumentation after 1 week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 27
Study: 37334864

Group type: EXPERIMENTAL
Intervention: Positive serum 1,3-β-D-glucan (BDG)
Number of subjects: 70
Study: 37335037

Group type: EXPERIMENTAL
Intervention: Internet-Based Training in Trauma Care for Nurses (IBTTCN)
Number of subjects: 41
Study: 37335139

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesenchymal-like ccRCC cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing and spatial transcriptomics
Number of subjects: 0
Study: 37335552

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF 675/150/200/10-mg FDC (test)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Coadministration of separate agents: darunavir 600 mg, cobicistat 150 mg, emtricitabine/tenofovir alafenamide 200/10-mg FDC (reference)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Coadministration of separate agents (reference)
Number of subjects: 37
Study: 37335604

Group type: EXPERIMENTAL
Intervention: Chatbot intervention with microinterventions
Number of subjects: 901

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 901
Study: 37335611

Group type: EXPERIMENTAL
Intervention: Voice-based digital health solution to monitor long COVID symptoms using vocal biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voice and vocal biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative web-based survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative phase based on semistructured individual interviews and focus groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-development of a tailored voice-based digital health solution
Number of subjects: 0
Study: 37335662

Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints ST36, ST37, ST39, PC6, LI4, and Liv 3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Shallow acupuncture on 12 non-acupoints (sham points)
Number of subjects: 60
Study: 37335751

Group type: EXPERIMENTAL
Intervention: Virtual Peer Groups
Number of subjects: 0